Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HCC Warrior Met Coal LLC

Market Closed 12-20 16:00:00 EST

54.93

-0.93

-1.66%

盘后54.93

+0.000.00%

16:36 EST

High56.01	Low54.40	Vol1.41M
Open54.64	D1 Closing55.86	Amplitude2.88%
Mkt Cap2.87B	Tradable Cap2.82B	Total Shares52.31M
T/O77.61M	T/O Rate2.74%	Tradable Shares51.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":54.93,"timestamp":1734728400000,"preClose":55.86,"halted":0,"volume":1408909,"hourTrading":{"tag":"盘后","latestPrice":54.93,"preClose":54.93,"latestTime":"16:36 EST","volume":100459,"amount":5518239.36,"timestamp":1734730619823},"delay":0,"floatShares":51380602,"shares":52311533,"eps":7.257717,"marketStatus":"Market Closed","change":-0.93,"latestTime":"12-20 16:00:00 EST","open":54.64,"high":56.01,"low":54.4,"amount":77606601.944476,"amplitude":0.028822,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.257717,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":55.86,"dividendRate":0.005644,"preHourTrading":{"tag":"盘前","latestPrice":54.9,"preClose":55.86,"latestTime":"09:29 EST","volume":1717,"amount":94889.977528,"timestamp":1734704998086},"postHourTrading":{"tag":"盘后","latestPrice":54.93,"preClose":54.93,"latestTime":"16:36 EST","volume":100459,"amount":5518239.36,"timestamp":1734730619823},"volumeRatio":2.0500885427265407,"impliedVol":0.487,"impliedVolPercentile":0.4167},"requestUrl":"/m/hq/s/HCC/tweets","defaultTab":"tweets","newsList":[{"id":"2492291581","title":"Barington nominates Mitarotonda and two others as directors at Matthews, sources say","url":"https://stock-news.laohu8.com/highlight/detail?id=2492291581","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492291581?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609600,"startTime":"0","endTime":"0","summary":"By Svea Herbst-Bayliss      NEW YORK, Dec 19 (Reuters) - Activist investor Barington Capital Management nominated its founder, James Mitarotonda, and two other executives with public board experience ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4131","LU1815336091.USD","FWRD","BK4113","BK4006","BK4137","LU0757428866.USD","LU1878469433.USD","ACI","MATW","HCC"],"gpt_icon":0},{"id":"2492185616","title":"Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185616","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492185616?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:30","pubTimestamp":1734528600,"startTime":"0","endTime":"0","summary":"- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec.  18, 2024  (GLOBE NEWSWIRE) -- C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/18/2999051/33333/en/Coherus-to-Present-Final-Phase-2-Casdozokitug-Combination-Data-in-Patients-with-Metastatic-Hepatocellular-Carcinoma-at-ASCO-GI-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4139","CHSCM","LU0053666078.USD","BK4107","WRD","CHSCO","PHH","BK4121","BK4189","HCC","CHRS","CHSCN","L","SEER","BK4535","BK4585","BK4588","CHSCL"],"gpt_icon":0},{"id":"2492902402","title":"Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492902402","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492902402?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:00","pubTimestamp":1734523200,"startTime":"0","endTime":"0","summary":"Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases. Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi’s existing cash and Cara’s anticipated cash balance, is expected to fund the combined company into the second half of 2026. Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma. “We are very excited to enter into this merger agreement with Tvardi and combine our financial resources with their","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2tNRAJ6nf.O5OoKpt5aVxw--~B/aD02ODt3PTI0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d220ec2dcbb4cdf82d1fff417fdd4acf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2tNRAJ6nf.O5OoKpt5aVxw--~B/aD02ODt3PTI0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d220ec2dcbb4cdf82d1fff417fdd4acf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cara-therapeutics-tvardi-therapeutics-announce-120000933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CARA","BK4007","BK4006","HCC"],"gpt_icon":0},{"id":"2491669462","title":"MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2491669462","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491669462?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:37","pubTimestamp":1734356220,"startTime":"0","endTime":"0","summary":"CHICAGO, December 16, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high-grade gliomas  as a drug for a \"rare pediatric disease.\". \"THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including pediatric high-grade glioma, which is among the most treatment-resistant cancers in children. THIO is shown to activate the immune system while evading tumor immunosuppression, a novel therapeutic approach for this devastating childhood disease,\" said MAIA Chairman and Chief Executive Officer Vlad Vitoc, M.D. \"We are proud to receive the FDA’s Rare Pediatric Disease designation for THIO, which significantly bolsters our plans for continuing research in the PDHGG indication.\". Rare pediatric disease priority review vouchers  can be redeemed by drug develop","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/o8xjZukNIGQajn16aQeq6Q--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a7941b4347fd25daca568f9a4279bf12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/o8xjZukNIGQajn16aQeq6Q--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a7941b4347fd25daca568f9a4279bf12"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-granted-fda-rare-133700877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IR","BK4139","LU0256863811.USD","BK4107","HCC","LU0053666078.USD","LU0124384867.USD","LU0256863902.USD","LU0417517546.SGD","BK4006","BK4588","MAIA","BK4183","BK4161","ODD","SG9999001440.SGD","BK4585","L","LU1978683503.SGD"],"gpt_icon":0},{"id":"2491660974","title":"Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660974","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660974?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:45","pubTimestamp":1734349500,"startTime":"0","endTime":"0","summary":"This approval marks the fourth non-small cell lung cancer  indication and the first indication in earlier stages of NSCLC for KEYTRUDA in China. \"While there have been several advances in the treatment of metastatic lung cancer over the past decade, lung cancer continues to be the leading cause of cancer death in China,\" said Dr. Heather Wakelee, principal investigator for KEYNOTE-671, thoracic medical oncologist and professor of medicine at Stanford University and past president of the International Association for the Study of Lung Cancer . \"This approval represents an important moment for certain patients with resectable NSCLC in China, providing a new option that has been shown in the KEYNOTE-671 study to significantly improve overall survival in these patients.\". This milestone builds on the momentum for worldwide approvals for KEYTRUDA in the perioperative setting for certain patients with earlier stages of NSCLC, including the European Union and Japan.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iNBE7NKOJEEiJDa13P.2KA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/18fb22972e5bd41c4a9830cf186549ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iNBE7NKOJEEiJDa13P.2KA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/18fb22972e5bd41c4a9830cf186549ba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-keytruda-pembrolizumab-approved-china-114500959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1057294990.SGD","IE0009355771.USD","LU2361044949.HKD","GRO","CPS","LU2023250504.SGD","SG9999002232.USD","LU1061106388.HKD","LU1116320737.USD","LU1291159041.SGD","AST","IE00BBT3K403.USD","BK4546","LU2361045086.USD","IE00BN8TJ469.HKD","SG9999015341.SGD","LU1066051498.USD","RCC","LU0070302665.USD","IE00BLSP4239.USD","SG9999001176.USD","BK4588","MRK","OS","HCC","HSCT","BK4007","BCG","IE00B4R5TH58.HKD","LU0965509010.AUD","LU1430594728.SGD","DM","LU0965509283.SGD","LU1934455863.HKD","LU2324357040.USD","BK4585","LU0203345920.USD","CRC","BK4599","LU1974910355.USD","LU1941712264.USD","BK4161","ALT","CRT","LU0265550359.USD","SG9999014567.USD","LU0861579265.USD","SG9999015358.SGD","SSI","BTC"],"gpt_icon":0},{"id":"2490385718","title":"Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2490385718","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490385718?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:30","pubTimestamp":1734010200,"startTime":"0","endTime":"0","summary":"Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T cell ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996206/0/en/Zymeworks-Hosts-R-D-Day-Highlighting-Continued-Clinical-Progress-in-Oncology-Programs-and-Expansion-into-Autoimmune-and-Inflammatory-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721429741.USD","CDE","BK4017","BK4006","LU0256331488.USD","BTC","ADC","DAR","BK4189","LU2380233275.USD","LU2211817866.USD","PRGS","LU1721429402.USD","BK4231","BK4097","BK4080","HCC","LU2065732104.USD","LU2308191902.HKD"],"gpt_icon":0},{"id":"2490379726","title":"Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490379726","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490379726?lang=en_us&edition=fundamental","pubTime":"2024-12-09 19:45","pubTimestamp":1733744700,"startTime":"0","endTime":"0","summary":"KEYTRUDA  plus chemotherapy followed by maintenance with LYNPARZA , with or without bevacizumab, demonstrated a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy alone. The study did not reach its secondary endpoint of overall survival. In the U.S., LYNPARZA has three approved indications in ovarian cancer: for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated  advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy; in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency -positive status defined by either a deleterious or s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t38YtUMlXYOC1qeNj8LjcA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f272383179f6e944ce37683c267abd9c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t38YtUMlXYOC1qeNj8LjcA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f272383179f6e944ce37683c267abd9c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-announces-phase-3-keylynk-114500835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GRO","LU1291159041.SGD","LU2461242641.AUD","URI","BK4135","IE00B66KJ199.SGD","SG9999001176.USD","LU1066051225.USD","MRK","BK4211","IE00BN8TJ469.HKD","HCC","HR","HSCT","LU0106261372.USD","AEIS","LU1023059063.AUD","LU1721428933.USD","CRC","BCG","LU0006306889.USD","PFS","LU1934455277.USD","LU2023250504.SGD","LU0203347892.USD","LU0208291251.USD","CPS","BK4195","LU1989771016.USD","OS","SG9999001440.SGD","SG9999014542.SGD","IE00BLSP4452.SGD","BTC","SG9999014575.USD","RCC","LU0266512127.USD","BK4516","BK4213","SG9999002224.SGD","LU1061106388.HKD","BK4124","ALT","DM","CRT","IE0031619046.USD","AST","LU0320765489.SGD","LU0965509283.SGD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2489784937","title":"Analysts Offer Insights on Materials Companies: Warrior Met Coal (HCC) and GoldMining (GLDG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489784937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489784937?lang=en_us&edition=fundamental","pubTime":"2024-12-08 16:50","pubTimestamp":1733647836,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Materials sector with new ratings on Warrior Met Coal (HCC – Research Report) and GoldMining (GLDG – Re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-materials-companies-warrior-met-coal-hcc-and-goldmining-gldg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-materials-companies-warrior-met-coal-hcc-and-goldmining-gldg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HCC","ARKG","BK4017","BK4006","BK4585","GLDG","BK4544"],"gpt_icon":0},{"id":"2489281992","title":"IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489281992","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489281992?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:00","pubTimestamp":1733486400,"startTime":"0","endTime":"0","summary":"Decision based on NIAGARA Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free and overall survival benefit. If approved, this will be the first and only perioperative immunotherapy regimen in this curative-intent setting. WILMINGTON, Del., December 06, 2024----AstraZeneca’s supplemental Biologics License Application  for IMFINZI  has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer .The Food and Drug Administration  grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.1 The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2025.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Y96NvJZo1Zs4mtkf0G8m.g--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f8947bcb3cc413367bda268ba3b4b52d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Y96NvJZo1Zs4mtkf0G8m.g--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f8947bcb3cc413367bda268ba3b4b52d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-granted-priority-review-120000304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4532","BK4023","BK4132","BK4007","LU0889565916.HKD","BK4500","TEN","HCC","LU2236285917.USD","LU2462157665.USD","BK4008","BK4588","LU0109394709.USD","ALK","BK4179","NICE","VOD","BK4585","HSCT","LU0320765992.SGD","LU2417539215.USD","OS","IO","BK4097","BTC","AZN","IE00BFMHRM44.USD","BK4144","BK4006","BK4563","LU1829250122.USD","LU2456880835.USD","BK4124","BK4568"],"gpt_icon":0},{"id":"2489542962","title":"RBC Raises Price Target on Warrior Met Coal to $75 From $70, Keeps Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2489542962","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489542962?lang=en_us&edition=fundamental","pubTime":"2024-12-06 19:35","pubTimestamp":1733484944,"startTime":"0","endTime":"0","summary":"Warrior Met Coal (HCC) has an average rating of overweight and mean price target of $77, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCC"],"gpt_icon":0},{"id":"2489545714","title":"IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489545714","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489545714?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:13","pubTimestamp":1733400780,"startTime":"0","endTime":"0","summary":"Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo. WILMINGTON, Del., December 05, 2024----AstraZeneca’s IMFINZI  has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer  whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.The approval was granted by the Food and Drug Administration  after securing Priority Review and Breakthrough Therapy Designation. It was based on results from the ADRIATIC Phase III trial which were presented during the Plenary Session of the 2024 American Society of Clinical Oncology  Annual Meeting and subsequently published in the New England Journal of Medicine.In the trial, IMFINZI reduced the risk of death by 27% versus placebo (based on an overall survival [OS] hazard ratio [HR] of 0.73; 95% confidence interval [CI] 0.57-0.93; P=0.01","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WdUPu.pyeoxWCQZadjtjSA--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/df2ccf3e0f1280ecf11bd3fe039136fd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WdUPu.pyeoxWCQZadjtjSA--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/df2ccf3e0f1280ecf11bd3fe039136fd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-approved-us-first-121300103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4179","HCC","BK4132","LU2236285917.USD","BK4563","BK4568","BK4585","BK4006","LU0109394709.USD","LU0320765992.SGD","BK4144","LU1829250122.USD","LU2456880835.USD","TEN","HSCT","LU2417539215.USD","AZN","BK4124","LU2462157665.USD","VOD","BK4532","LU0889565916.HKD","IO","BK4588","BK4007"],"gpt_icon":0},{"id":"2488162503","title":"8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488162503","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488162503?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313600,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, Dec. 04, 2024  -- Can-Fite BioPharma Ltd.  , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced today that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite’s Phase II Liver Cancer Study has an overall survival time of 8 years with a complete response.Can-Fite is currently enrolling patients in Israel, Europe and the US for a pivotal Phase III clinical study for patients with advanced HCC as a 2nd or 3rd line treatment and Namodenoson is administered twice daily orally. The study protocol has been agreed upon with U.S. Food and Drug Administration  and European Medicines Agency .Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for the treatment of HCC. A compassionate use program has been ongoing in Israel and Romania.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sJtGBGhYav13.OX82J5L2A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6114327b6294df8bacb7f8b771866c2b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sJtGBGhYav13.OX82J5L2A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6114327b6294df8bacb7f8b771866c2b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/8-years-survival-complete-cure-120000894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","BK4139","HCC","BK4157","CANF","BK4006","AEIS","IE0031619046.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2488140509","title":"Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2488140509","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488140509?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:00","pubTimestamp":1733230800,"startTime":"0","endTime":"0","summary":"Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990578/0/en/Relay-Therapeutics-and-Elevar-Therapeutics-Announce-Exclusive-Global-Licensing-Agreement-for-Lirafugratinib-in-FGFR2-Driven-Cholangiocarcinoma-and-Other-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RLAY","CCA","BK4563","BK4006","HCC"],"gpt_icon":0},{"id":"2488391696","title":"Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million  to Intas Pharmaceuticals Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488391696","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488391696?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":"- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund deve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990450/33333/en/Coherus-Announces-Agreement-to-Divest-UDENYCA-Franchise-for-up-to-558-million-to-Intas-Pharmaceuticals-Ltd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4189","BK4535","CHSCL","CHSCN","BK4139","CHSCO","CHSCM","CHRS","HCC","WRD","BK4006"],"gpt_icon":0},{"id":"2488950378","title":"Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2488950378","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488950378?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144400,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc.  , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has completed mouse model studies providing proof-of-concept for the Company's K1.1 mRNA product as a novel therapeutic agent for human hepatocellular carcinoma.Human hepatocellular carcinoma  is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several systematic treatment options were available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.This press release contains forward-looking statements which are","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8EqTpkrD9ySyesXGAkIE4A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f9d0e63f90af4de7babd149b6ffd6fba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8EqTpkrD9ySyesXGAkIE4A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f9d0e63f90af4de7babd149b6ffd6fba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-announces-breakthrough-research-130000971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCC","SBFMW","SBFM","WRD","BK4006","BK4139"],"gpt_icon":0},{"id":"2486803311","title":"ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2486803311","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486803311?lang=en_us&edition=fundamental","pubTime":"2024-11-28 00:29","pubTimestamp":1732724940,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that its supplemental new drug application  for cabozantinib will be discussed at an Oncologic Drugs Advisory Committee  meeting in March 2025.The sNDA is seeking approval for the drug to treat adults with previously treated advanced pancreatic neuroendocrine tumors  and advanced extra-pancreatic NET .Exelixis’ shares have surged 48.9% year to date against the industry’s decline of 7.8%.The company was notified of the update on the ODAC meeting by the FDA. ODACs mostly review and evaluate data regarding the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and make recommendations to the Commissioner of Food and Drugs.Per EXEL, the planned ODAC meeting is not related to the currently approved indications for Cabometyx in the United States.In August 2024, the FDA granted cabozantinib orphan drug designation for the treatment of pNET and assigned a target action date of April 3, 2025.EXEL’s Effort","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/odac-discuss-exelixis-application-cabometyx-162900490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","LU1061106388.HKD","SPRO","BK4006","LU1066051225.USD","SG9999001176.SGD","SG9999001176.USD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU0861579265.USD","LU0965509010.AUD","LU0965509101.SGD","BK4139","EXEL","IE00BN8TJ469.HKD","SG9999014567.USD","LU2361044865.SGD","BK4550","LU1989772840.SGD","LU1116320737.USD","MRK","LU1037948541.HKD","RCC","IE00BFTCPJ56.SGD","BK4007","LU1989771016.USD","LU2089984988.USD","SG9999001440.SGD","LU0058720904.USD","SG9999014542.SGD","LU2023250504.SGD","HCC","LU1093756325.SGD","LU0203345920.USD","LU0211331839.USD","LU2361045086.USD","LU1037948897.HKD","LU1291159041.SGD","LU0265550359.USD","LU2023250843.SGD","LU0122379950.USD","DTC","IE00BSNM7G36.USD","PFS","BK4195","LU2361044949.HKD","LU0234572021.USD","LU0238689110.USD","CSTL","LU1934455863.HKD"],"gpt_icon":0},{"id":"2486841428","title":"Warrior Met Coal, Inc.'s (NYSE:HCC) Intrinsic Value Is Potentially 24% Below Its Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2486841428","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486841428?lang=en_us&edition=fundamental","pubTime":"2024-11-27 18:23","pubTimestamp":1732702980,"startTime":"0","endTime":"0","summary":"Warrior Met Coal's estimated fair value is US$52.13 based on 2 Stage Free Cash Flow to Equity. Warrior Met Coal's US$68.88 share price signals that it might be 32% overvalued. The US$76.00 analyst price target for HCC is 46% more than our estimate of fair value. In this article we are going to estimate the intrinsic value of Warrior Met Coal, Inc.  by projecting its future cash flows and then discounting them to today's value. Our analysis will employ the Discounted Cash Flow  model. Don't get put off by the jargon, the math behind it is actually quite straightforward.Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.Present Value of Terminal Value = TV / ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/w2t1xoPraquUCzh5JCiwDw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/073fc6331af6400e3dbbb4524a7bb84d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/w2t1xoPraquUCzh5JCiwDw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/073fc6331af6400e3dbbb4524a7bb84d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/warrior-met-coal-inc-nyse-102300964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4100","FCF","TV","NYSE","DCF","HCC","BK4211","BK4006"],"gpt_icon":0},{"id":"2486802837","title":"Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2486802837","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486802837?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:05","pubTimestamp":1732655100,"startTime":"0","endTime":"0","summary":"ALAMEDA, Calif., November 26, 2024----Exelixis, Inc.  today announced that the U.S. Food and Drug Administration  has notified the company that the supplemental New Drug Application  for cabozantinib  for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors  and advanced extra-pancreatic NET  will be discussed at an Oncologic Drugs Advisory Committee  meeting in March 2025. The sNDA is based on the final results of the phase 3 CABINET pivotal trial, conducted by the National Cancer Institute's National Clinical Trials Network, evaluating cabozantinib compared with placebo in advanced pNET and advanced epNET. In August 2024, Exelixis announced that the FDA granted orphan drug designation to cabozantinib for the treatment of pNET and assigned a Prescription Drug User Fee Act target action date of April 3, 2025.CABINET is a multicenter, randomized, double-blinded, placebo-controlled phase 3 pivotal trial that had enrolled a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NfaTzDmvT0eJL8eYMcz_hg--~B/aD0zMjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6c4e447b5cbe087a283f0710d603479e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NfaTzDmvT0eJL8eYMcz_hg--~B/aD0zMjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6c4e447b5cbe087a283f0710d603479e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-provides-regulatory-related-supplemental-210500287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXEL","RCC","BK4211","BK4202","BK4195","NCI","BK4588","BK4116","PFS","NET","LU2286300806.USD","BK4157","IE0031619046.USD","BK4139","BK4532","IE00B7SZL793.SGD","BK4006","DTC","BK4190","BK4548","AEIS","BK4585","BK4560","BK4554","HCC","IE00B19Z4B17.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2485294516","title":"Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2485294516","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485294516?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:23","pubTimestamp":1732292580,"startTime":"0","endTime":"0","summary":"Replimune GroupREPL announced that it has submitted a biologics license application  to the FDA forits lead pipeline candidate, RP1, in combination withBristol Myers’BMY blockbuster immuno-oncology drug Opdivo  to treat adult patients with anti-PD1 failed advanced melanoma. The regulatory filing has been made under the FDA’s Accelerated Approval pathway. In response to the encouraging news, the stock rose 19.4% in the after-market hours on Thursday. The stock is also rising today during the pre-market hours.RP1 is based on a proprietary strain of herpes simplex virus, engineered and genetically armed with a fusogenic protein  and GM-CSF, intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.REPL’s RP1 BLA Submission Supported by Robust Study Data. Replimune’s BLA submission for RPI, in combination with Bristol Myers’ Opdivo, for the advanced melanoma indication is supported by positive top-line res","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/replimune-stock-rallies-bla-filing-162300397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BSNM7G36.USD","LU1066053197.SGD","BK4588","LU1032466523.USD","LU1430594728.SGD","LU1868836591.USD","IE0009355771.USD","LU2360032135.SGD","IE00BFTCPJ56.SGD","BK4581","PFE","SG9999002232.USD","LU1894683348.USD","LU0170899867.USD","LU1883839398.USD","LU1585245621.USD","IE00BLSP4239.USD","ALLO","LU1670711040.USD","SG9999002224.SGD","SGXZ57979304.SGD","BK4007","SG9999001176.SGD","LU2242646821.SGD","BK4139","IE0002270589.USD","SG9999011175.SGD","LU0868494617.USD","BK4585","LU0114720955.EUR","LU0237698245.USD","LU0306806265.USD","LU0985481810.HKD","LU1057294990.SGD","BK4559","IE00BLSP4452.SGD","HCC","BMY","BK4532","LU1261432733.SGD","IE00BJJMRZ35.SGD","LU0234572021.USD","IE00B19Z3581.USD","LU1718418525.SGD","REPL","SG9999013999.USD","IE0002141913.USD","LU1093756168.USD","BK4505","LU0289739699.SGD"],"gpt_icon":1},{"id":"2485265051","title":"60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2485265051","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485265051?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:00","pubTimestamp":1732284000,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc.  and Can-Fite BioPharma Ltd.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.In an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss the company's mission to develop and commercialize new therapies for infectious diseases. He highlights the FDA-approved antimalarial drug ARAKODA  and outlines plans to expand its indications to address other diseases, including babesiosis. Dow also emphasizes the company's commitment to addressing unmet medical needs and improving global health outcomes.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-fite-biopharma-140000300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","BK4100","BK4561","BK4006","AIRI","TV","SXTP","BK4144","BK4585","03160","BK4555","TM","HCC","ET","CANF","BK4588","SXTPW","BK4099","BK4187","BK4590"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.warriormetcoal.com","stockEarnings":[{"period":"1week","weight":-0.1081},{"period":"1month","weight":-0.2149},{"period":"3month","weight":-0.0029},{"period":"6month","weight":-0.1068},{"period":"1year","weight":-0.1055},{"period":"ytd","weight":-0.0991}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.063019},{"month":2,"riseRate":0.571429,"avgChangeRate":0.001096},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.052653},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.008197},{"month":5,"riseRate":0.5,"avgChangeRate":0.019887},{"month":6,"riseRate":0.625,"avgChangeRate":0.009748},{"month":7,"riseRate":0.75,"avgChangeRate":0.070216},{"month":8,"riseRate":0.375,"avgChangeRate":-0.000702},{"month":9,"riseRate":0.625,"avgChangeRate":0.034067},{"month":10,"riseRate":0.5,"avgChangeRate":0.036694},{"month":11,"riseRate":0.625,"avgChangeRate":0.072271},{"month":12,"riseRate":0.75,"avgChangeRate":0.051239}],"exchange":"NYSE","name":"Warrior Met Coal LLC","nameEN":"Warrior Met Coal LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Warrior Met Coal LLC,HCC,Warrior Met Coal LLC股票,Warrior Met Coal LLC股票老虎,Warrior Met Coal LLC股票老虎国际,Warrior Met Coal LLC行情,Warrior Met Coal LLC股票行情,Warrior Met Coal LLC股价,Warrior Met Coal LLC股市,Warrior Met Coal LLC股票价格,Warrior Met Coal LLC股票交易,Warrior Met Coal LLC股票购买,Warrior Met Coal LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction